We’ve got a big gap up working today. QQQQ is threatening its February highs in the pre-market largely thanks to GOOG’s 4% post-earning’s pop. So things look pretty bullish right now but the big question is will the close look as bullish. Let’s see if the Nasdaq can close above the February high.
Having said all of that, I’m out of here — it’s options expiration day and that means a non-trading day for me…
On Today’s Calendar:
- nothing
More Calendars: U.S. Earnings | Conf. Calls | Surprises | IPO | Economic
Potential swing trades:
See one of the recent ‘Chart Reading‘ posts for some potential swing candidates.
Potential day trades:
(From Briefing.com)
Gapping Down
Gapping down on weak earnings/guidance: MNT -18.3% (also downgraded to Underperform at Piper), RNOW -16.9% (also multiple downgrades), RHI -10.0% (also downgraded to Sell at Stifel), STMP -9.5% (also downgraded to Neutral at First Albany), ENER -8.2% (guides Q3 revs below consensus, announces organizational restructuring plan), SIRF -6.7%, COF -5.5% (also multiple downgrades), CREE -1.6%… Other news: EVVV -5.5% (prices 8.75 mln share offering at $19/share), HDNG -3.4% (prices 2.2 mln share secondary at $23.50), AVCI -2.1% (continuing weakness after Wednesday’s report & restructuring announcement), HTLD -2.1% (downgraded to Hold at Stifel), DPTR -1.9% (prices 6.2 mln share offering at $20.50/share), TZOO -1.8% (downgraded to Buy at First Albany).
Gapping Up
Gapping up on strong earnings/guidance: SYNL +11.6%, INFA +5.0%, CAT +4.9%, ISRG +3.9%, PKTR +2.5%… M&A: GCO +12.2% (Foot Locker proposes acquisition of GCO for $46/share in cash)… Rebound in Asian stock markets lift China stocks, particularly solar: JADE +6.6%, TSL +5.5%, SOLF +4.0%, JASO +3.6%… Small-cap cancer/biotech stocks continue their news-driven rally: EPCT +81.6% (announces Myriad Genetics presented studies characterizing vascular disruption capabilities of Azixa), AVNR +9.7% (momentum), MGRM +7.7% (tgt raised to $3 at ThinkEquity), AMRN +6.4% (momentum), CBLI +6.2% (Protectan CBLB612 demonstrates efficacy in stimulating proliferation and mobilization of bone marrow stem cells in primate model), POZN +5.9% (initiated with a Buy and $28 tgt at Citi), NSTK +5.5% (Cramer positive on stock), ENZN +5.1% & SKYE +3.5% (ENZN granted full approval for DepoCyt for treatment of Lymphomatous Meningitis; ENZN licensed North American rights from SKYE)… Other news: HRB +8.8% (announces agreement to sell Option One Mortgage), RMKR +5.1% (prices 4.16 mln share offering at $8.50/share), HSOA +4.7% (profiled in BusinessWeek), NAPS +4.6% (Circuit City teams with NAPS to launch new digital music service).
Disclaimer & How I use this list
